Introduction
Cochlear implants (CI), which are composed of an electrode array for direct stimulation of the cochlear nerve, are well established for the effective treatment of sensory deafness. The quality of the signal transmission however highly depends on the impedance which can be affected by connective tissue around the CI electrodes. Another important point is the maintenance of the residual intact spiral ganglion cells and therefore the rest hearing [1] . With the purpose to prevent fibrosis and to enhance the spiral ganglion cell growth, a specific CI surface modification enabling the simultaneous release of antiproliferative/anti-inflammatory drugs such as dexamethasone and nerve growth factors like the brain-derived neurotrophic factor (BDNF) would be desirable [2] . This however affords a biofunctionalization method allowing sustained BDNF release from CI surfaces, which are provided by poly(4-hydroxybutyrate) (P(4HB)), a DMS-releasing coating as exemplarily [3] . In general, reversible biomolecule immobilization on polymer surfaces can be established as shown in Figure 1 . As covalent attachment might be most promising for long-term drug release, we propose the use of the crosslinker disuccinimidyl suberate (DSS) to covalently attach BDNF to P(4HB) surfaces. DSS is a homobifunctional N-hydroxy-succinimide ester that preferentially reacts with amine groups under formation of stable amides but also at a diminished rate with hydroxyl groups yielding hydrolyzable ester bonds [4] . BDNF release can be thus enabled via hydrolyzable chemical bonds.
Methods

Generation of reactive groups at P(4HB) surfaces
Planar P(4HB) samples (TephaFLEX®, M w =170000 g/mol, Tepha, Inc., USA) were prepared via solution casting. For modification experiments, test specimens of a diameter of 6 mm were cut from the prepared films and treated with O 2 -plasma or degraded with 0.25 mol/L NaOH/EtOH (1:1) according to [5] .
Attachment of DSS to the P(4HB) surface
Dry dimethylsulfoxide (DMSO), tetrahydrofuran (THF) or ethyl acetate (EE) were used as solvents. Untreated and NaOH degraded P(4HB) surfaces were treated with 500 µL of 1 µg/mL DSS solution at 25 °C for 3 h. Reaction with sodium 4-hydroxybutyrate (4HB-Na) served as a positive control.
Characterization of the reaction efficiency
For evaluation of the coupling efficiency, concentration of DSS after crosslinking was analyzed by liquid chromatography-mass spectrometry (LC-MS) and compared to DSS in solution without reactant (reference). For a first indication of DSS hydrolysis as important parameter for drug release, DSS decomposition in water was evaluated. Therefore, DSS was stored at a concentration of 100 ng/mL at 15 °C for 19 h and analyzed by LC-MS at periodic time intervals. Attachment of BDNF to the untreated and DSS-modified P(4HB)-surface P(4HB) samples were put into a 1 µg/mL BDNF solution in phosphate-buffered saline (PBS) pH 7.6 for 16 h at 4°C.
In-vitro BDNF release
In order to simulate the conditions of the inner ear a quasi-stationary release model (non-sink conditions) was used [3] to release BDNF in artificial perilymph pH 7,3 (formulation according to [6] ). The released BDNF concentration was subsequently determined by an ELISA.
Results
Results of the reaction efficiency of DSS are shown in Figure 2 . The concentration of DSS decreased the most during reaction with the positive control 4HB-Na in DMSO. In EE and in THF the reaction with 4HB-Na leads to no significant decrease in DSS concentration. Hence, DMSO is ruled out as the most convenient solvent and has been used for further experiments. Interestingly, no significant differences were observed between degraded and untreated P(4HB) surfaces with regard to reaction efficiency with DSS ( Figure 2) . Stability studies of DSS in water revealed that DSS decomposes over 19.5 h to an extent of nearly 75% in an exponential fashion (Figure 3) . Disparities in the release behavior of physically adsorbed and covalently attached BDNF are indicated in figure 4 . While a rather exponential release profile was recognized from untreated P(4HB)-surfaces, covalently attached BDNF showed a linear release within the first 96 h.
Discussion
4HB-Na is the sodium salt of the monomer of P(4HB) and hence displays the maximum number of reactive groups towards the crosslinking reaction with DSS. Thus, the impact on the concentration of DSS was assumed to be the maximum in comparison to the reaction with the polymer. This effect was only observed in DMSO, indicating an inhibitory effect of the other solvents. DMSO seems to be hence appropriate for the modification of P(4HB) with DSS. Moreover, we were able to trace the cleavage of the crosslinker DSS in aqueous medium by LC-MS, which is a requirement for the establishment of a sustained drug release. This could be confirmed by in vitro drug release studies, evidencing a linear release profile of covalently attached BDNF:
In conclusion, the presented results are promising for the development of a specially tailored CI-associated LDD system for the enhancement of spiral ganglion cells after CI insertion into the inner ear.
